Obesity Surgery

, Volume 17, Issue 7, pp 989–992

Carcinoid Syndrome Misdiagnosed as a Malabsorptive Syndrome after Biliopancreatic Diversion

  • E. M. López-Tomassetti Fernández
  • I. Arteaga González
  • H. Díaz Luis
  • A. Carrillo Pallarés
Case Report
  • 41 Downloads

Abstract

A case is reported of a woman who developed untreatable diarrhea after a prior biliopancreatic diversion (BPD), attributed to the malabsorptive component. Abdominal ultrasound incidentally found focal liver lesions. On fine needle aspiration biopsy, atypia was found, and these hepatic lesions were resected with free margins. The specimen showed liver metastases of an aggressive malignant neuroendocrine neoplasm. The primary site was subsequently identified to be in the pancreas. The physician and surgeon must realize that non-related diseases can develop after bariatric surgery, as in the general population.

Key words

Morbid obesity bariatric surgery biliopancreatic diversion neuroendocrine cancer carcinoid syndrome liver metastases cancer 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fontaine KR, Redden DT, Wang C, et al. Years of life lost due to obesity. JAMA 2003; 289: 187–93.PubMedCrossRefGoogle Scholar
  2. 2.
    Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 2005; 6: 283–96.PubMedCrossRefGoogle Scholar
  3. 3.
    Adami HO, Trichopoulos D. Obesity and mortality from cancer. N Engl J Med 2003; 348: 1623–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Alvarez GC, Faria EN, Beck DT et al. Laparoscopic spleen preserving distal pancreatectomy as treatment for nesidioblastosis after gastric bypass surgery. Obes Surg 2007; 17: 550–2.PubMedCrossRefGoogle Scholar
  5. 5.
    Valverde I, Puente J, Martin-Duce A et al. Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects. Obes Surg 2005; 15: 387–97.PubMedCrossRefGoogle Scholar
  6. 6.
    Scopinaro N, Gianetta E, Civalleri D et al. Bilio-pancreatic bypass for obesity: II. Initial experience in man. Br J Surg 1979; 66: 618–20.PubMedCrossRefGoogle Scholar
  7. 7.
    Scopinaro N, Adami GF, Marinari GM et al. Biliopancreatic diversion. World J Surg 1998; 22: 936–46.PubMedCrossRefGoogle Scholar
  8. 8.
    DeRoover A, Detry O, Desaive C et al. Risk of upper gastrointestinal cancer after bariatric operations. Obes Surg 2006; 16: 1656–61.CrossRefGoogle Scholar
  9. 9.
    Keshishian A, Hamilton J, Hwang L et al. Carcinoid tumor and bariatric surgery. Obes Surg 2002; 12: 874–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Service GJ, Thompson GB, Service FJ et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353: 249–54.PubMedCrossRefGoogle Scholar
  11. 11.
    Cummings DE. Gastric bypass and nesidioblastosis – too much of a good thing for islets? N Engl J Med 2005; 353: 300–2.PubMedCrossRefGoogle Scholar
  12. 12.
    Lamounier RN, Pareja JC, Tambascia MA et al. Incretins: clinical physiology and bariatric surgery – correlating the entero-endocrine system and a potentially anti-dysmetabolic procedure. Obes Surg 2007; 17: 569–76.PubMedCrossRefGoogle Scholar
  13. 13.
    Stewart ID, Flaks B, Watanapa P et al. Pancreatobiliary diversion enhances experimental pancreatic carcinogenesis. Br J Cancer 1991; 63: 63–6.PubMedGoogle Scholar
  14. 14.
    Watanapa P, Efa EF, Beardshall K et al. Inhibitory effect of a cholecystokinin antagonist on the proliferative response of the pancreas to pancreatobiliary diversion. Gut 1991; 32: 1049–51.PubMedCrossRefGoogle Scholar
  15. 15.
    Morisset J, Julien S, Laine J. Localization of cholecystokinin receptor subtypes in the endocrine pancreas. J Histochem Cytochem 2003; 51: 1501–13.PubMedGoogle Scholar
  16. 16.
    Howatson AG, Carter DC. Pancreatic carcinogenesisenhancement by cholecystokinin in the hamster-nitrosamine model. Br J Cancer 1985; 51: 107–14.PubMedGoogle Scholar
  17. 17.
    Smith JP, Kramer ST, Solomon TE. CCK stimulates growth of six human pancreatic cancer cell lines in serum-free medium. Regul Pept 1991; 32: 341–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Reubi JC. CCK receptors in human neuroendocrine tumors: clinical implications. Scand J Clin Lab Invest Suppl 2001; 234: 101–4.PubMedGoogle Scholar
  19. 19.
    Holdstock C, Engstrom BE, Ohrvall M et al. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab 2003; 88: 3177–83.PubMedCrossRefGoogle Scholar
  20. 20.
    Adami GF, Cordera R, Andraghetti G et al. Changes in serum ghrelin concentration following biliopancreatic diversion for obesity. Obes Res 2004; 12: 684–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Volante M, Allia E, Gugliotta P et al. Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab 2002; 87: 1300–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Zagury L, Moreira RO, Guedes EP et al. Insulinoma misdiagnosed as dumping syndrome after bariatric surgery. Obes Surg 2004; 14: 120–3.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2007

Authors and Affiliations

  • E. M. López-Tomassetti Fernández
    • 1
  • I. Arteaga González
    • 1
  • H. Díaz Luis
    • 1
  • A. Carrillo Pallarés
    • 1
  1. 1.Department of Gastrointestinal SurgeryHospital Universitario de Canarias (HUC)Canary IslandsSpain
  2. 2.Department of SurgeryHospital Universitario de CanariasCanary IslandsSpain

Personalised recommendations